Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202-Reference-Cited by-同舟云学术

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202

Published:2017-06 Issue:2 Volume:98 Page:296-303
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Lawton Colleen A.F.,Lin Xiaolei,Hanks Gerald E.,Lepor Herbert,Grignon David J.,Brereton Harmar D.,Bedi Meena,Rosenthal Seth A.,Zeitzer Kenneth L.,Venkatesan Varagur M.,Horwitz Eric M.,Pisansky Thomas M.,Kim Harold,Parliament Matthew B.,Rabinovitch Rachel,Roach Mack,Kwok Young,Dignam James J.,Sandler Howard M.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference19 articles.

1. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long term results of phase III RTOG 8531;Pilepich;Int J Rad One Biol & Phys,2005

2. Phase III radiation therapy oncology group (RTOG) trial 8610 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate;Pilepich;Int J Radiat Oncol Biol Phys,2001

3. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial;Bolla;Lancet,2002

4. Duration of androgen suppression in the treatment of prostate cancer;Bolla;N Engl J Med,2009

5. Phase III trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. The RTOG protocol 9202;Hanks;Joum Clin One,2003

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis;European Urology;2024-07

2. What is the key factor determining effectiveness of radiotherapy for high-risk prostate cancer: a hidden message from RTOG 0521;Translational Andrology and Urology;2024-04

3. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1;JU Open Plus;2024-04

4. Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer;World Journal of Urology;2024-03-16

5. Hypofractionated radiation therapy combined with androgen deprivation therapy for high‐risk localized prostate cancer;Journal of Medical Imaging and Radiation Oncology;2024-03-13